8-K: Microbot Medical Secures $4.2 Million from Series G Option Exercises

Microbot Medical Inc. announced the issuance of 2,395,715 common shares, generating approximately $4.2 million in gross proceeds from the exercise of Series G preferred investment options.

Summary

• Since July 17, 2025, Microbot Medical Inc. issued an aggregate of 2,395,715 shares of its common stock.
• The shares were issued upon the exercise of outstanding Series G preferred investment options by their holders.
• The exercise price for the Series G Options was $1.75 per share.
• The exercise generated gross proceeds to the company of approximately $4.2 million, before deducting placement agent fees and expenses.
• The shares were issued under the exemption provided in Section 4(a)(2) of the Securities Act of 1933, as transactions not involving a public offering.
• The shares underlying the Series G Options were previously registered by the company for resale on a Registration Statement on Form S-3 (Registration No.: 333-284688) on behalf of the holders.

Sentiment

Score: 7

Explanation: The filing reports a positive inflow of capital from the exercise of existing options, which strengthens the company's cash position. While not a new strategic initiative, it represents a successful conversion of financial instruments into funding.

Positives

• The company received approximately $4.2 million in gross proceeds, strengthening its financial position.
• The exercise of Series G options indicates a commitment from option holders, converting potential equity into actual capital.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future operations or financial performance.

Industry Context

This filing details a routine capital raise through the exercise of existing options, a common method for companies to secure funding for ongoing operations, research and development, or general corporate purposes without issuing new equity directly to the public. It reflects the conversion of previously granted financial instruments into common equity and cash.

Stakeholder Impact

• Shareholders: The issuance of new shares from option exercises could lead to minor dilution of existing shareholdings, but the capital raised strengthens the company's balance sheet, potentially supporting future growth and operations.

Key Dates

Keywords

Microbot Medical, MBOT, equity, shares, capital raise, option exercise, Series G options, common stock, SEC filing, 8-K